CHIMERA
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
CHIMERA: A Flexible and Scalable 3.1 TOPS/W AI-MCU with Transformer Accelerator and 563 Gb/s Shared-L2 Memory Subsystem with QoS Guarantees
arXiv:2606.02358v1 Announce Type: new Abstract: We present Chimera, a flexible and scalable Microcontroller Unit (MCU) designed to accelerate real-time inference of rapidly evolving transformer-based models at the ultra-low-power edge (hundred of mW). The chip, implemented in 22 nm FDX technology, integrates a transformer accelerator tightly coupled within a compute cluster featuring nine general-purpose RV32IMA cores. Scalability extends to the memory hierarchy through a novel L2 memory...
Chimera: Protocol-Aware Recovery for Confidential BFT Consensus
arXiv:2606.09101v1 Announce Type: new Abstract: Trusted Execution Environments (TEEs) have enabled confidential Byzantine Fault-Tolerant (BFT) consensus systems with confidentiality and improved scalability. However, TEEs do not provide state continuity: during recovery, a compromised host can roll back a crashed enclave to a stale persistent state, significantly threatening both safety and availability. Existing defenses face a fundamental tradeoff: they either impose substantial overhead...
CHIMERA-Bench: A Benchmark Dataset for Epitope-Specific Antibody Design
arXiv:2603.13431v3 Announce Type: replace Abstract: Computational antibody design has seen rapid methodological progress, with dozens of deep generative methods proposed in the past three years, yet the field lacks a standardized benchmark for fair comparison and model development. These methods are evaluated on different SAbDab snapshots, non-overlapping test sets, and incompatible metrics, and the literature fragments the design problem into numerous sub-tasks with no common definition. We...
Structure-Aware Prediction of PROTAC-Mediated Protein Degradability via Graph Neural Networks
Announce Type: cross Abstract: Proteolysis-targeting chimeras (PROTACs) can selectively degrade disease-causing proteins, yet predicting which targets are amenable to degradation remains a critical bottleneck: existing computational methods require the complete PROTAC molecular structure, information unavailable before synthesis. We present DegradoMap, a graph neural network that predicts PROTAC-mediated degradability from protein structure and E3 ligase identity alone -- the minimal...
Gut Microbiota Dysbiosis Drives Myocardial Hypertrophy Through GBP2b/GBP1-Mediated Immune Reprogramming and Exosomal Signaling in Chronic Colitis
BACKGROUND: Patients with inflammatory bowel disease (IBD) are at increased risk of cardiovascular disease, yet the mechanisms linking chronic intestinal inflammation to cardiac dysfunction remain poorly understood. IBD is characterized by profound gut microbiota dysbiosis, which we hypothesize drives systemic immune dysregulation and contributes to cardiac dysfunction. A chronic colitis mouse model was used to assess gut microbiota dysbiosis, systemic immune cell metabolism, and cardiac...
A 170 km journey by a freshwater stingray challenges long-held conservation assumptions
June 8, 2026 dialog A 170 km journey by a freshwater stingray challenges long-held conservation assumptions Lisa Lock Scientific Editor Robert Egan Associate Editor Most sharks and rays inhabit the oceans, but a small proportion thrive in freshwater. Approximately 4% to 5% of all shark and ray species live in tropical and subtropical rivers around the world. Two main ecological strategies can be distinguished among freshwater sharks and rays.
Amazon Luna adds Hollow Knight to its catalog for June
Amazon Luna adds Hollow Knight to its catalog for June It’s also offering Mafia III and some remastered Tomb Raider as free PC titles. We may receive a commission on purchases made from links. Amazon Luna has dropped its additions for June, and there are some solid titles joining the lineup for the game streaming service.
Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer
Abstract BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and frequent treatment resistance and relapse1,2,3.